JP2005502332A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502332A5
JP2005502332A5 JP2003515664A JP2003515664A JP2005502332A5 JP 2005502332 A5 JP2005502332 A5 JP 2005502332A5 JP 2003515664 A JP2003515664 A JP 2003515664A JP 2003515664 A JP2003515664 A JP 2003515664A JP 2005502332 A5 JP2005502332 A5 JP 2005502332A5
Authority
JP
Japan
Prior art keywords
ggmg
polypeptide fragment
seq
fragment
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003515664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2002/003407 external-priority patent/WO2003010314A2/en
Publication of JP2005502332A publication Critical patent/JP2005502332A/ja
Publication of JP2005502332A5 publication Critical patent/JP2005502332A5/ja
Pending legal-status Critical Current

Links

JP2003515664A 2001-07-26 2002-07-25 Gmg−2ポリヌクレオチド及びポリペプチド並びにそれらの使用 Pending JP2005502332A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30825301P 2001-07-26 2001-07-26
US30921001P 2001-07-31 2001-07-31
US31527701P 2001-08-27 2001-08-27
PCT/IB2002/003407 WO2003010314A2 (en) 2001-07-26 2002-07-25 Gmg-2 polynucleotides and polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2005502332A JP2005502332A (ja) 2005-01-27
JP2005502332A5 true JP2005502332A5 (enExample) 2005-11-17

Family

ID=27405306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003515664A Pending JP2005502332A (ja) 2001-07-26 2002-07-25 Gmg−2ポリヌクレオチド及びポリペプチド並びにそれらの使用

Country Status (7)

Country Link
US (1) US20060293225A1 (enExample)
EP (1) EP1436392A2 (enExample)
JP (1) JP2005502332A (enExample)
AU (1) AU2002321768B2 (enExample)
CA (1) CA2453653A1 (enExample)
IL (1) IL159872A0 (enExample)
WO (1) WO2003010314A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478890T1 (de) * 2002-05-31 2010-09-15 Serono Genetics Inst Sa Homotrimerer, erweiterter globulärer kopf von obg3 und verwendungen davon
US20040242566A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
MXPA06001601A (es) 2003-08-13 2006-08-25 Takeda Pharmaceutical Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
SI1942898T2 (sl) 2005-09-14 2014-08-29 Takeda Pharmaceutical Company Limited Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20110112186A1 (en) * 2008-02-29 2011-05-12 Isis Innovation Limited Diagnostic methods
US9817001B2 (en) 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
AU2012322018B2 (en) 2011-10-13 2017-09-21 Boston Heart Diagnostics Compositions and methods for treating and preventing coronary heart disease
US9730980B2 (en) * 2012-07-25 2017-08-15 University Of Cincinnati Method of treating type I diabetes using apolipoprotein A-IV
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
CA2968221A1 (en) 2014-11-17 2016-05-26 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139686A0 (en) * 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999064629A1 (en) * 1998-06-12 1999-12-16 Smithkline Beecham Corporation Acrp30r2, a homolog of acrp30 (30 kd adipocyte complement-related protein)
AU5134799A (en) * 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
AU5037100A (en) * 1999-05-27 2000-12-18 Zymogenetics Inc. Adipocyte complement related protein homolog zacrp6
JP2004522402A (ja) * 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same

Similar Documents

Publication Publication Date Title
JP2005502332A5 (enExample)
RU2207874C9 (ru) Производное инсулина или его физиологически приемлемая соль, предшественник производного инсулина, днк-последовательность, кодирующая предшественник, вектор экспрессии, содержащий упомянутую днк-последовательность, субстрат, трансформированный упомянутым вектором экспрессии, фармацевтическая композиция с понижающей, соответственно регулирующей уровень глюкозы в крови эффективностью
JP2014510518A5 (enExample)
JP2002206000A5 (enExample)
JP2018171063A5 (enExample)
JP2003501022A5 (enExample)
JP2013520426A5 (enExample)
JP2019527200A5 (enExample)
FI3256579T3 (fi) Kysteiiniproteaasi
JP2009213477A5 (enExample)
JP2011526303A5 (enExample)
JP2004525608A5 (enExample)
JP2008511323A5 (enExample)
JP2006514104A5 (enExample)
PE20190355A1 (es) Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
CA2502904A1 (en) Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
JP2011502964A5 (enExample)
JP2007504144A5 (enExample)
JP2012505902A5 (enExample)
JP2003501068A5 (enExample)
JP2004521123A5 (enExample)
JP2006502702A5 (enExample)
JP2020518249A5 (enExample)
JP2005511038A5 (enExample)
RU2007119376A (ru) Тимус - специфический белок